Stefano Ginanni Corradini, Walter Elisei, Rosanna De Marco, Maria Siciliano, Massimo Iappelli, Francesco Pugliese, Franco Ruberto, Francesco Nudo, Renzo Pretagostini, Alessandro Bussotti, Gianluca Mennini, Annarita Eramo, Francesca Liguori, Manuela Merli, Adolfo Francesco Attili, Andrea Onetti Muda, Stefania Natalizi, Pasquale Berloco, Massimo Rossi – 21 January 2005 – A total of 44 donor/recipient perioperative and intraoperative variables were prospectively analyzed in 89 deceased‐donor liver transplantations classified as initial good graft function (IGGF) or initial poor graft function

Shimon Kusne, Jerry Smilack – 21 January 2005

Silvina E. Yantorno, Eva B. Varela, Sebastián R. Raffa, Valeria I. Descalzi, Maria L. Gomez Carretero, Daniel A. Pirola, Andres E. Ruf, Gretel I. Martinez Carabuz, Luis G. Podesta, Federico G. Villamil – 21 January 2005 – The mean time to peak absorption of cyclosporine (CsA) in liver transplant patients is approximately 2 hours, but in some patients the peak occurs later. The goal of this study was, therefore, to investigate the incidence of delayed absorption in 27 de novo liver transplant recipients receiving CsA ≥10 mg/kg/day (C2 monitoring) and in 15 maintenance patients.

21 January 2005

Virginie Fouquet, Arnaud Alves, Sophie Branchereau, Sophie Grabar, Dominique Debray, Emmanuel Jacquemin, Denis Devictor, Philippe Durand, Catherine Baujard, Monique Fabre, Danielle Pariente, Christophe Chardot, Bertrand Dousset, Pierre‐Philippe Massault, Denis Bernard, Didier Houssin, Olivier Bernard, Frédéric Gauthier, Olivier Soubrane – 21 January 2005 – The aim of this study was to review our experience in orthotopic liver transplantation (OLT) for biliary atresia (BA) in children and analyze the survival and prognostic factors, and long‐term outcome.

Paul J. Thuluvath – 21 January 2005

Thomas F. Baumert, Chun Yang, Peter Schürmann, Josef Köck, Christian Ziegler, Carsten Grüllich, Michael Nassal, T. Jake Liang, Hubert E. Blum, Fritz von Weizsäcker – 19 January 2005 – Hepatitis B virus (HBV) core promoter mutations have been implicated in the pathogenesis of fulminant hepatitis B. Due to the limited availability of primary human hepatocytes, the functional characterization of HBV mutants has been performed predominantly in transformed cells, which may not represent ideal model systems for studying virus–cell interactions.

Thomas D. Boyer, Ziv J. Haskal – 19 January 2005

Lars Zender, Sebastian Hütker, Bettina Mundt, Morlen Waltemathe, Christian Klein, Christian Trautwein, Nisar P. Malek, Michael Peter Manns, Florian Kühnel, Stefan Kubicka – 19 January 2005 – Inhibition of NFκB enhances the susceptibility of cancer to TRAIL‐mediated apoptosis and is suggested as a strategy for cancer therapy. Because the role of NFκB in TRAIL‐mediated apoptosis of hepatocytes is unknown, we investigated the influence of NFκB‐inhibition in death ligand‐mediated apoptosis in hepatitis.

Barbara Akhurst, Vance Matthews, Kirsten Husk, Mark J. Smyth, Lawrence J. Abraham, George C. Yeoh – 19 January 2005 – The liver regenerates after acute injury via hepatocyte cell division; during chronic injury, when hepatocyte replication is impaired or blocked, liver progenitor oval cells mediate liver regeneration. If both regeneration options are blocked in animal models, then liver failure and death ensues. The mechanisms underlying oval cell induction, proliferation, and subsequent liver regeneration remain poorly characterized.